Mace L. Rothenberg, MD, recently stepped down as Chief Medical Officer of Pfizer, a post he had held since 2019. Prior to that role at Pfizer, Dr. Rothenberg was Head of Clinical Development & Medical Affairs for Oncology from 2008 to 2016, and Chief Development Officer for Oncology from 2016 to 2018. During that time, his organization developed and obtained regulatory approval for 11 new cancer medicines, including first-in-class medicines Ibrance (palbociclib) for patients with HR+/HER2- advanced breast cancer and Xalkori (crizotinib) for patients with ALK+ non-small cell lung cancer.
Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008. From 1991 to 1998, he was Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio and Executive Officer of the Southwest Oncology Group.
Dr. Rothenberg is the recipient of the first Craig Saxton Lifetime Achievement Award from Pfizer, the Lane W. Adams Quality of Life Award from the American Cancer Society and the Statesman Award from the American Society of Clinical Oncology. He is board-certified in Internal Medicine and Medical Oncology and is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.
Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982. He received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute.